Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, ...

Third Quarter 2024 Results Key Financial Results Revenue: €1.24b (up 39% from 3Q 2023).

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a ...

Last week, you might have seen that BioNTech SE ( NASDAQ:BNTX ) released its quarterly result to the market. The ...

German pharmaceutical company BioNTech was back in profit in the third quarter of 2024, it announced on Monday, with comparatively early approvals for adapted coronavirus vaccines driving up sales.

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 billion, largely driven by the successful launch of its variant ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.